NEW
Firazyr

Firazyr

icatibant

Manufacturer:

Takeda

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Icatibant
Indications/Uses
Symptomatic treatment of acute attacks of hereditary angioedema in adults, adolescents & childn ≥2 yr, w/ C1-esterase-inhibitor deficiency.
Dosage/Direction for Use
SC Adult Single inj of 30 mg, may administer 2nd & 3rd inj at 6-hr intervals in case of insufficient relief or symptom recurrence. Max: 3 inj in 24 hr period. Childn & adolescent 2-17 yr & weighing >65 kg 30 mg, 51-65 kg 25 mg, 41-50 kg 20 mg, 26-40 kg 15 mg, 12-25 kg 10 mg.
Contraindications
Special Precautions
1st treatment should be given in a medical institution or under physician's guidance for patients who have never received Firazyr previously. Patients w/ laryngeal attacks; acute ischemic heart disease or unstable angina pectoris; history of or recent stroke. Minor influence on the ability to drive & use machines. Breastfeeding women should not breastfeed for 12 hr after treatment. Pregnancy. Childn <2 yr or weighing <12 kg. Elderly >65 yr.
Adverse Reactions
Inj site reactions. Dizziness, headache; nausea; rash, erythema, pruritus; pyrexia; increased transaminases.
Drug Interactions
Possible enhancement of bradykinin levels w/ ACE inhibitors.
ATC Classification
B06AC02 - icatibant ; Belong to the class of drugs used in the treatment of hereditary angioedema.
Presentation/Packing
Form
Firazyr soln for inj 30 mg/3 mL
Packing/Price
3 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in